Piramal Pharma Ltd.
NSE: PPLPHARMA · Pharmaceuticals
Snapshot
Unlock Piramal Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Piramal Pharma Limited is a pharmaceutical company that provides a diverse portfolio of products and specialised services, including high-potency active pharmaceutical ingredients (HPAPI) and injection manufacturing. The company operates as a subsidiary of Piramal Enterprises Limited and is headquartered in Mumbai.
Business Model
The company generates revenue through a combination of pharmaceutical product sales and contract development and manufacturing organisation (CDMO) services. It leverages its technical capabilities in complex manufacturing to serve global healthcare clients.
Growth Outlook
Growth is expected to be driven by the expansion of its CDMO service offerings and the scaling of its specialised pharmaceutical product portfolio. The company continues to focus on enhancing its manufacturing capabilities to meet global demand.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent global regulatory standards and potential inspections by bodies such as the US FDA.
- Supply Chain Volatility. Disruptions in the global supply chain for raw materials and active pharmaceutical ingredients could adversely impact production timelines and margins.
- Currency Fluctuation. As a company with significant international operations, exposure to foreign exchange rate volatility may impact financial performance.
- Competitive Pricing. Intense competition within the pharmaceutical services sector may exert downward pressure on pricing and contract margins.
Start your research today
Unlock AI insights, financials, peers and live data on Piramal Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,205 Cr
TTM · consolidated
NET PROFIT
₹-314 Cr
TTM · consolidated
EPS
₹-2.37
TTM · consolidated
RETURN ON EQUITY
-3.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
1.4%
TTM · consolidated
P/E
-90.4x
Q1 FY27 · consolidated
EV/EBITDA
26.2x
Q1 FY27 · consolidated
EBITDA MARGIN
13.6%
TTM · consolidated
NET PROFIT MARGIN
-3.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.7x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Piramal Pharma Ltd.PPLPHARMA | ₹28,520 Cr | -90.39 | 26.16 | 0.8% | 13.6% | -3.9% | 1.4% | +7.7% |
Wockhardt Ltd.WOCKPHARMA | ₹33,940 Cr | 82.88 | 40.10 | 18.4% | 25.1% | 8.9% | 10.4% | +41.5% |
Sai Life Sciences Ltd.SAILIFE | ₹33,605 Cr | 92.27 | 47.96 | — | 31.2% | 15.7% | 19.8% | +86.7% |
Rubicon ResearchRUBICON | ₹29,245 Cr | 99.68 | 63.32 | — | 23.9% | 22.4% | 27.6% | — |
Neuland Laboratories Ltd.NEULANDLAB | ₹29,073 Cr | 58.41 | 36.78 | 78.3% | 33.5% | 29.3% | 35.4% | +55.1% |
Acutaas Chemicals LtdACUTAAS | ₹25,941 Cr | 67.17 | 45.18 | 40.9% | 39.0% | 26.1% | 34.3% | +122.4% |
As of Q1 FY27
Financials
Piramal Pharma Ltd.
NSE: PPLPHARMA · Pharmaceuticals
Snapshot
Unlock Piramal Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Piramal Pharma Limited is a pharmaceutical company that provides a diverse portfolio of products and specialised services, including high-potency active pharmaceutical ingredients (HPAPI) and injection manufacturing. The company operates as a subsidiary of Piramal Enterprises Limited and is headquartered in Mumbai.
Business Model
The company generates revenue through a combination of pharmaceutical product sales and contract development and manufacturing organisation (CDMO) services. It leverages its technical capabilities in complex manufacturing to serve global healthcare clients.
Growth Outlook
Growth is expected to be driven by the expansion of its CDMO service offerings and the scaling of its specialised pharmaceutical product portfolio. The company continues to focus on enhancing its manufacturing capabilities to meet global demand.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent global regulatory standards and potential inspections by bodies such as the US FDA.
- Supply Chain Volatility. Disruptions in the global supply chain for raw materials and active pharmaceutical ingredients could adversely impact production timelines and margins.
- Currency Fluctuation. As a company with significant international operations, exposure to foreign exchange rate volatility may impact financial performance.
- Competitive Pricing. Intense competition within the pharmaceutical services sector may exert downward pressure on pricing and contract margins.
Start your research today
Unlock AI insights, financials, peers and live data on Piramal Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,205 Cr
TTM · consolidated
NET PROFIT
₹-314 Cr
TTM · consolidated
EPS
₹-2.37
TTM · consolidated
RETURN ON EQUITY
-3.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
1.4%
TTM · consolidated
P/E
-90.4x
Q1 FY27 · consolidated
EV/EBITDA
26.2x
Q1 FY27 · consolidated
EBITDA MARGIN
13.6%
TTM · consolidated
NET PROFIT MARGIN
-3.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.7x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27